Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)

About Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Cyclacel Pharmaceuticals logoCyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYCC
  • CUSIP: N/A
  • Web:
Average Prices:
  • 50 Day Moving Avg: $5.38
  • 200 Day Moving Avg: $4.71
  • 52 Week Range: $3.05 - $10.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.10
  • P/E Growth: 0.00
  • Net Margins: -1,041.60%
  • Return on Equity: -87.61%
  • Return on Assets: -64.72%
  • Current Ratio: 4.05%
  • Quick Ratio: 4.05%
  • Average Volume: 823,870 shs.
  • Beta: 3.36

Frequently Asked Questions for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

How often does Cyclacel Pharmaceuticals pay dividends? What is the dividend yield for Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals declared an annual dividend on Thursday, June 9th. Shareholders of record on Sunday, July 17th will be given a dividend of $0.15 per share on Monday, August 1st. The ex-dividend date is Wednesday, July 13th. View Cyclacel Pharmaceuticals' Dividend History.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Shares of Cyclacel Pharmaceuticals reverse split before market open on Tuesday, May 31st 2016. The 1-12 reverse split was announced on Friday, May 27th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 27th 2016. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) announced its earnings results on Thursday, May, 11th. The company reported ($0.38) earnings per share for the quarter. Cyclacel Pharmaceuticals had a negative net margin of 1,041.60% and a negative return on equity of 87.61%. View Cyclacel Pharmaceuticals' Earnings History.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a decline in short interest in April. As of April 28th, there was short interest totalling 392,506 shares, a decline of 29.3% from the April 13th total of 554,919 shares. Based on an average daily volume of 110,915 shares, the short-interest ratio is presently 3.5 days. Approximately 9.5% of the company's shares are sold short.

Who are some of Cyclacel Pharmaceuticals' key competitors?

Who owns Cyclacel Pharmaceuticals stock?

Cyclacel Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include TANG CAPITAL PARTNERS LP (13.20%). View Institutional Ownership Trends for Cyclacel Pharmaceuticals.

How do I buy Cyclacel Pharmaceuticals stock?

Shares of Cyclacel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cyclacel Pharmaceuticals stock cost?

One share of Cyclacel Pharmaceuticals stock can currently be purchased for approximately $4.87.

Analyst Ratings

Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/12/2016HC WainwrightReiterated RatingBuyN/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Earnings by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Earnings History by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.38)ViewN/AView Earnings Details
3/28/2017Q4 2016($0.73)($0.69)$0.21 million$0.28 millionViewN/AView Earnings Details
11/14/2016Q316($0.94)($0.86)$0.42 million$0.21 millionViewN/AView Earnings Details
8/10/2016Q216($1.01)$0.22 millionViewListenView Earnings Details
5/11/2016Q116($0.09)$512.00 million$139.00 millionViewListenView Earnings Details
3/24/2016Q4($0.08)($0.10)$0.51 million$0.42 millionViewListenView Earnings Details
11/12/2015Q315($0.09)($0.08)$0.30 million$0.72 millionViewListenView Earnings Details
8/11/2015Q215($0.10)$0.30 millionViewListenView Earnings Details
5/12/2015Q115($0.25)($0.19)$0.51 millionViewListenView Earnings Details
3/24/2015Q414($0.26)($0.21)$0.25 millionViewN/AView Earnings Details
11/11/2014Q314($0.26)($0.22)$0.74 millionViewN/AView Earnings Details
8/12/2014Q214($0.28)($0.22)$0.36 millionViewN/AView Earnings Details
5/13/2014Q114($0.24)($0.25)$0.40 millionViewN/AView Earnings Details
3/25/2014Q413($0.33)($0.19)$0.09 million$0.30 millionViewN/AView Earnings Details
11/12/2013Q3($0.31)($0.31)ViewListenView Earnings Details
8/14/2013Q2 2013($0.10)$0.03 million$0.26 millionViewN/AView Earnings Details
5/13/2013Q1 2013($1.18)ViewN/AView Earnings Details
11/12/2012Q312($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Current Year EPS Consensus Estimate: $-2.25 EPS
Next Year EPS Consensus Estimate: $-1.57 EPS


Current Dividend Information for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Most Recent Dividend:8/1/2016
Annual Dividend:$0.15
Dividend Yield:3.08%
Payout Ratio:-2.80% (Trailing 12 Months of Earnings)
-6.67% (Based on This Year's Estimates)
-9.55% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Dividend History by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 18.78%
Insider Trades by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Insider Trades by Quarter for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017Kevin C TangMajor ShareholderBuy134,200$4.34$582,428.00View SEC Filing  
11/20/2014Sam L BarkerDirectorBuy3,100$3.00$9,300.00View SEC Filing  
5/21/2013Lloyd SemsDirectorBuy33,333$3.00$99,999.00View SEC Filing  
5/21/2013Paul McbarronCFOBuy12,948$3.03$39,232.44View SEC Filing  
5/21/2013Spiro George RombotisInsiderBuy100,000$3.00$300,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)
DateHeadline logoCyclacel Pharmaceuticals Inc (CYCC) Short Interest Update - May 13 at 7:44 AM logo22 Stocks Moving In Friday's Pre-Market Session - Benzinga - May 12 at 5:09 PM logoEdited Transcript of CYCC earnings conference call or presentation 11-May-17 8:30pm GMT - May 12 at 5:09 PM logoCyclacel Pharmaceuticals Inc (CYCC) Releases Quarterly Earnings Results - May 12 at 3:12 PM logoCyclacel Pharmaceuticals' (CYCC) CEO Spiro Rombotis on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha - May 12 at 3:20 AM logoInvestor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - May 11 at 5:18 PM logoCyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results - May 5 at 7:43 AM logoPositive Media Coverage Somewhat Likely to Impact Cyclacel Pharmaceuticals (CYCC) Stock Price - April 29 at 9:35 PM logoCyclacel Pharmaceuticals Inc (CYCC) Cut to Hold at Zacks Investment Research - April 26 at 7:24 PM logoCyclacel Pharmaceuticals (CYCC) Receives News Impact Score of 0.04 - April 25 at 4:51 PM logoCompany News for April 11, 2017 - April 11 at 12:58 PM logoETFs with exposure to Cyclacel Pharmaceuticals, Inc. : April 5, 2017 - April 7 at 9:19 AM logoBUZZ-U.S. STOCKS ON THE MOVE-Yingli Green, Calix, Hertz Global, Cyclacel Pharma - Nasdaq - April 3 at 5:02 PM logoCyclacel Pharmaceuticals Inc. (CYCC) Is Spiking Higher On CYC065 News - RTT News - April 3 at 5:02 PM logoCyclacel's CYC065 Succeeds in Lung Cancer Study - April 3 at 5:02 PM logoCyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by ... - Yahoo Finance - April 2 at 9:32 PM logoEdited Transcript of CYCC earnings conference call or presentation 28-Mar-17 8:30pm GMT - March 29 at 11:54 AM logoAfter-Hours Earnings Report for March 28, 2017 : PLAY, VRNT, OLLI, SONC, WLB, AST, IZEA, CYCC - Nasdaq - March 28 at 4:23 PM logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement - March 28 at 4:23 PM logoQ4 2016 Cyclacel Pharmaceuticals Inc Earnings Release - After Market Close - March 28 at 12:18 PM logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events - March 13 at 4:43 PM logoCyclacel Pharma (CYCC) CDK Inhibitor CYC065 Causes Anaphase Catastrophe Featured in JNCI Publication - - March 9 at 5:11 PM logoCyclacel Pharmaceuticals: Is There Anything Left In The Tank? - Seeking Alpha - March 9 at 5:11 PM logoCyclacel’s CDK Inhibitor CYC065 Causes Anaphase Catastrophe, a Novel Cancer-Specific Mechanism of Action, in Research Published in JNCI - March 7 at 12:04 PM logo7:03 am Cyclacel Pharma announces the publication of a peer-reviewed journal article featuring the company's cyclin dependent kinase 2/9 (CDK2/9) inhibitors; 'preclinical data demonstrated that both Cyclacel's CYC065 and CCT68127 demonstrat - March 7 at 12:04 PM logoCyclacel Plunges on Leukemia Drug Failure (CYCC) - February 24 at 12:00 PM logoCyclacel Tanks on Leukemia Drug Failure - February 24 at 12:00 PM logoCyclacel Pharma (CYCC) Pivotal Phase 3 SEAMLESS Study in Elderly Patients With AML Doesn't Meet Primary Endpoint - February 23 at 9:39 PM logo6:57 am Cyclacel Pharma announces its Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia did not meet its primary endpoint - February 23 at 9:39 PM logoCyclacel's leukemia drug for elderly patients fails in key study - February 23 at 9:39 PM logoCyclacel's stock plunges after disappointing trial results of its cancer treatment - February 23 at 9:39 PM logoCYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - February 23 at 9:39 PM logoBUZZ-US STOCKS ON THE MOVE-Tesla, L Brands, Nvidia, Cyclacel - Nasdaq - February 23 at 4:37 PM logoMid-Day Market Update: AXT Rises After Strong Q4 Results; Cyclacel Pharma Shares Tumble - Nasdaq - February 23 at 4:37 PM logoCyclacel Pharmaceuticals (CYCC) Presents at 19th Annual BIO CEO & Investor Conference - February 14 at 5:26 PM logoUnusual 11 Mid-Day Movers 12/27: (MBRX) (CYCC) (RADA) Higher; (ELGX) (SGEN) (GSAT) Lower (more...) - December 27 at 4:51 PM



Cyclacel Pharmaceuticals (CYCC) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff